London based Healthcare Giant set to be the new promoters of Dr. Datsons Labs Ltd

London based Healthcare Giant set to be the new promoters of Dr. Datsons Labs Ltd. Dr. Datsons Labs aggressive marketing & new orders worth over 400 crores will sail through with the new Cash Rich Promoters

Debashish Mishra

 

It is widely known that Dr. Datsons Labs Ltd is in the process of one time settlement with the Bank which is to the tune of only 80 crores & clearly the assests of the company can easily be valued at about 175 Crores . With the new London based promoter coming on Board to take control of the company for a complete overhaul where the management of the company is already in place with a professionally managed top management & the work force of 250 employees. The present structure of the company is run by institutions spearheaded by  Dr. Rajendra Kamat as the Vice-Chairman & MD, Mr Saleem Talim as the CEO, & Mr. Shashikant B. Shinde as Executive Director. Mr. Mahesh Vaidya has been appointed as Non Executive Chairman of the Company with effect from February 15, 2015 as per the company’s announcement to the BSE. The top level sources to the London based healthcare Firm’s leadership reveal that a deal has indeed been stuck with Dr. Datsons Labs Ltd for an undisclosed amount, but a definite picture of recovery back to business. The deal involves the taking over of the company as new promoter Group. The London based Company besides having operations worldwide is also setting up a huge $200m multi-specialty hospital in Mumbai for cancer and trauma surgery, due to be commissioned in August 2015. The Group clearly wants to use Dr. Datsons Labs Ltd by making it as a hub to supply quality medicines to the world market. The old clients of Dr. Datsons Labs will also make a comeback to do business with a reasonable price offering high quality standards..

Sources close to Pharmaleaders reveal that a big time London based group having worldwide operations with a total value of more than 5 Billions $ with interest in Healthcare, finance, banking operations is indeed set to take over Dr. Datsons Labs. The talks between the two companies are almost complete where the London based company has constituted a project management group consisting of consultants of repute in healthcare as well as financial background well versed with the present market conditions. It is believed that the new promoters will streamline the operations with manufacturing, production, R&D, NDDS, NCE’s & additional capabilities to foray into cancer research. The present  valuation of the company is definitely much bigger & the regular business will be hassle free once the new promoter group list the stocks outside india. The  Regulatory & statutory Bodies in Singapore or in London stock exchanges are definitely  far better than India & the company can post a turnover of  500 Crores. The New formation will retain the top management executives.

It may be recalled that with the new management in Board, the company has bagged some of the most enviable orders from both overseas & domestic companies to exports in anti-malarial & anti-cancer drugs. Some of the top orders include Eubage Laboratory, the Belgium-based manufacturer of nutrients and nutritional supplements,  to invest $ 17 million (about Rs 104 crore) 20 nutraceutical products to be manufactured at their Pune formulations facilities, an estimated 80 crore order from Yemen’s Al-Mugdh Pharma for anti-malarial drugs, partnership with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015. Lately Dr. Datsons Labs also received order from a Delhi based exports company through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd to be exported to Europe. In addition to this Dr. Datsons Labs Ltd has already on board some top domestic players such as Glenmark, Universal Healthcare, Pharmed Europe, Ltd. and Zenufa Labs among others. To the advantage of the Acquirer are some top facilities. Dr Datson’s core strength lies in the research and manufacture of quality lozenges, controlled substances in formulations, anti-malarials and niche APIs. And CRAMS . The Company’s culture of manufacturing excellence is centered on quality control, quality assurance, in-process control guidelines and training. Corporate Performance Review of the Company The Company’s manufacturing locations are integrated and linked by high-speed networks to deliver products to markets at the right time and price. The Company’s facilities are UK-MHRA and EU-GMP-compliant, and ISO 9001:2008, ISO 14001:2004 and ISO 22000- certified; these enhance the confidence of global Pharma players. The Company designed the quinine extraction equipment in-house while maintaining stringent quality parameters, emerging as one of the most cost-effective quinine manufacturers. The Quinine Sulphate and other salts received approvals from US, EU and Canadian customers.

Dr Datsons Labs

The reason for the company to sell the business to the London based group is quite clear that the company has been facing liquidity issues for Its working Capital Requirement, hence performance of manufacturing operations are greatly affected , to overcome the same Dr. Datsons Labs had undertaken steps to raise equity through sale of stake , bringing in strategic investors and even selling the assets so that the company gets in required funding for its Working Capital & Capex Program. Dr. Datsons was looking for long term investors who can take forward the legacy of the company.

 

Ochoa Labs to Expand base in Europe through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd

Ochoa Labs to Expand base in Europe through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr. Datsons Labs Ltd

 

Dr. Datsond Labs Ltd will manufacture on an exclusive basis to the Ochoa Labs Requirements of DOCETAXEL ANHYDROUS,IRINOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE,SEMI SYNTHETIC PACLITAXEL, GEMCITABINE HYDROCHLORIDE, CAPECITABINE, IMATINIB MESYLATE GEFITINIB in finished formulations

Thursday, March 21, 2015, Mumbai, Maharashtra, India : . Dr. Datsons Labs Ltd, HSL Code: AANLIF, BSE Code: 533412, NSE Symbol: DRDATSONS,ISIN INE928K01013 has forged a potential collaboration with Delhi based Pharma Company Ochoa Laboratories Ltd to produce oncology drugs to cater to the European market worth 120 Crore. Dr. Datsons Labs has received the letter on 11th March 2015 for undertaking the contract manufacturing of the cancer drugs on a stipulated time line.

Speaking on the development, Dr. Rajendra Kamat, Vice-Chairman & MD of Dr Datsons Labs Ltd said “ We are excited about the latest order confirmation from Ochoa Labs which was there in the proposal since a year & all our clinical data & dossiers are accepted &  we are  committed to manufacturing excellence in Cancer products at par excellence . As a premier oncology manufacturer from India, we are particular about maintaining the quality of our medicines so that they match international standards. We manufacture cancer treatment medicines at affordable prices so that it is available universally to all affected patients. As a manufacturer of medicines dedicated to treating cancer, we cover the entire gamut of medication including tablets, capsules, injections and ointments. These drugs are used in chemotherapy, immunotherapy, surgery or hormone therapy. Like other formulations, our cancer drugs are prepared under strict hygienic conditions. Manufacture of oncologic formulations are done keeping in mind the exact form of therapy needed. The formulations and their strengths vary accordingly. Each drug is carefully examined and tested keeping in compliance with leading drug manufacturing standards. We procure ingredients from authentic sources so as to maintain highest quality standards of our products. Several tests are conducted so as to ensure genuineness of our drugs and formulations. We maintain national as well as international standards of quality of EU-GMP or UK-MHRA, WHO-GMP and many others.

“The real challenge will be to run the second plant with full capacity which will necessitate additional  manpower & resources. Though the plant is fully equipped, our biggest challenge will be to meet the quality parameters of the guidelines. We are hopeful for a long lasting relationship with Ochoa Labs which will be a continued & steady source of revenue & our top line growth will increase in the last quarter of the fiscal” said Dr. Rajendra Kamat in the release.

Sunil Chopra, Director, Ochoa Laboratories Ltd, said, “We believe that the coming together of Dr. Datsons’s innovative oncology range with Ochoa’s strong persecute in Europe  empowers us to provide an even wider array of value driven healthcare solutions & We are extremely optimistic about its prospects and committed to creating a long-term partnership with Dr. Datsons Labs”. Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies.”.

 

“We have received orders to export the anti cancer drugs to Europe & since we don’t have a specialized plant on this to exports products such as DOCETAXEL ANHYDROUS,IRINOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE,SEMI SYNTHETIC PACLITAXEL,, Dr. Datsons facilities are ideal for us to source the finished formulations under our brand name to sell in regions such as UK, Germany, France, Italy and Spain under one distribution point in London. We will laso have an advantage of getting the sourcing from Dr. Datsons Labs at a reasonable rate compared to other Contract Manufacturing Companies producing Anti-Cancer Drugs.” We will start commercializing the products in Europe in the third quarter of 2015 & our commitment to the export market is to make the product available in Nov Dec 2015”.

cancer-drug-on-banner copy

It may be recalled that a new study point out the growing requirements of cancer drugs in the European region & more than 500,000 patients across the five largest European countries such as UK, Germany, France, Italy and Spain have been treated with a new form of personalised cancer drug, according to new research. It found that between 500,000 and 600,000 patients are currently treated with targeted therapies in these countries, all of which have a total population of around 320m. In the five countries studied, Cegedim’s analysis found targeted therapies represent an average of 32% of all cancer drugs used – the remaining 68% being cheaper chemotherapy drugs and hormonal treatments, Breast cancer is the most commonly treated, accounting for around 16% of all tumours across all five countries. Non-small cell lung cancer (NSCLC) was a close second, although the rates of targeted drug use for the disease varied greatly among the individual countries.In France the use was 15% while it was 12.3% in Italy and Germany, but 11% in Spain and only 7.1% in the UK. In fact the UK had the lowest level of cancer patients using these new types of treatments, with 67.9%. Spain had the highest level at 71.9%, followed closely by Italy with 71.6%. Cegedim says that these differences are influenced by the launch dates of the drugs, as well as the health authority and market access policies in each country. Patients with pancreatic cancer, for which there are few personalised drugs licensed in Europe, made the least use of personalised medicines, with only around 2.5% of patients across the five countries receiving new treatments for the disease.

 

About Ochoa Laboratories Ltd

 

Ochoa Laboratories Ltd. operates as a pharmaceutical company in India. It offers pharmaceutical formulations and dosage forms, including vasoprotectors, dermatology products, antibiotics, and antioxidants and nutritional supplements. The company has operations in Europe, Tanzania, Zambia, Uganda, Venezuela, Costa Rica, and various Latin American countries. Ochoa Laboratories Pvt. Ltd. was incorporated in 1993 and is based in Noida, India with an additional office in New Delhi. In 2009 Ranbaxy Laboratories Ltd acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Ltd for its entire range of dermatological and lifestyle products for the domestic marketing.  Presently Ochoa Laboratories only is engaged in the export market & we have widened our marketing to Europe in a big way.

Dr Manmohan Singh’s role as a accuser in Coal Scam a ploy to save real scamstars?

A special court on Tuesday asked the Central Bureau of Investigation (CBI) to examine ex-Prime Minister Manmohan Singh in a case related to irregularity in allocating a coal block in which Aditya Birla Group Chairman Kumar Mangalam Birlaand former coal secretary P C Parakh were named.In October 2013, when the CBI had registered this case, it triggered a huge controversy as Singh’s role was also questioned by the opposition parties.  Back then, Singh was quick to officially react to the allegations by issuing a press statement from the Prime Minister’s Office (PMO) within a few days of the registering of the case.In his defence, Singh maintained that he is “satisfied that the final decision taken in this regard was entirely appropriate and is based on the merits of the case placed before him.”
The case relates to the allocation of Talabira-II and -III coal blocks jointly to Hindalco Industries (an Aditya Birla Group company) and with two other firms in Odisha’s Jharsuguda district in 2005. During this period, Singh was holding additional charge of the coal ministry.Business Standard takes a look at Singh’s version of one of the most controversial coal block allocation.

Merit in the case

Chalking out the sequence of events, Singh said that the Talbaria coal block allocation was a case where “ the final decision differed from the earlier recommendation of the Screening Committee, and this was done following a representation received in the Prime Minister’s Office from one of the parties, which was referred to the Ministry of Coal.”

Screening Committee’s first rejection

According to Singh, initially Birla (then non-executive chairman of Hindalco) had written to him (letter dated 7 May 2005) for allotment of Talabira II coal block in Odisha to Hindalco. Acknowledging the letter, Singh asked Birla to get a report from the coal ministry. Birla wrote another letter in June 2005 “repeating the request”, also writing to the coal ministry to send the report on the matter.

In August 2005, the Ministry of Coal had replied to the PMO saying that the Screening Committee, headed by Parakh, had recommended that the Talabira coal block be allocated to Neyveli Lignite Corporation (NLC) and not Hindalco as “adequate coal linkages had been provided to Hindalco from Mahanadi Coalfields Ltd. (MCL) a long time back and Hindalco had not used the coal.”

The committee had proposed that “NLC & Mahanadi Coalfields Ltd. can develop the two blocks together as one large mine through a Joint Venture (JV).”

However, Birla’s contention was that his company was the first one to apply for the block in 1996 and “the coal linkage granted earlier was not used as a bauxite mine lease relating to the aluminium plant had not materialized.” In fact, Birla further mentioned that “the Government of Odisha favoured allocation of Talabira-II to Hindalco in preference to NLC.”

Odisha government’s strong support

“While the file was being processed in PMO, the Prime Minister received a letter dated 17 August 2005 from the Chief Minister of Odisha (Naveen Patnaik) on the allotment of Talabira-II to Hindalco,” Singh said in the press statement.

In the letter, Patnaik had said that his government (also part of the standing committee deliberation) had given “topmost priority” to Hindalco and had “strongly supported the case.”
The reasons cited by the Patnaik government were that aluminium plants generate more jobs and create more wealth for the country compared to independent power plants. “The letter urged that these special considerations be kept in mind and the matter examined expeditiously,” the PMO said.

File returned

The PMO, on 29 August 2005, returned the coal ministry’s earlier recommendation of not allocating the coal block to Hindalco and asked the ministry to re-examine the matter in the light of Patnaik’s letter and resubmit the file.
In September 2005, the coal ministry re-submitted its recommendation and this time decided to allocate Talabira II & III as a single mine through a JV formed between Mahanadi Coalfields, NLC & Hindalco with equity shareholding of 70 per cent, 15 per cent and 15 per cent respectively. Accordingly, 70 per cent of the production was decided to be handed over to Mahanadi Coalfields and the rest equally to NLC and Hindalco.
“The satisfaction level of NLC would be 29 per cent of its total requirement and of Hindalco, 81.5 per cent,” the coal ministry had said.
The equity formula
The coal ministry stated the following as one of the reasons for the above recommendations, “NLC may not be dropped as it is a Central PSU already recommended by the Screening Committee. Hindalco’s case for allocation has been strongly recommended by the State Government and it has also been an early applicant.” The ministry re-instated that the Odisha government had clearly preferred Hindalco over others.
It further admitted that as a result of such an arrangement in allocating the coal block, “Hindalco’s satisfaction level is about 80 per cent, whereas NLC’s is much lower” adding further that the full needs of NLC could be met from Mahanadi Coalfields’ reserves in Talabira-III.
According to Singh, while processing the proposal, the PMO had noted that ownership pattern was not in correspondence with the guidelines approved by him in June 2005 which “required this ratio to be in proportion to the assessed requirement of coal of each allocatee. As per this guideline, the NLC:Hindalco ratio in their 30 per cent share should be 22.5:7.5 and not 15:15 as was proposed.”
However, the coal ministry said, “As for the NLC and HINDALCO equity ratio in the JV, it would require relaxation of guidelines that were approved by PM earlier, but this could be considered as NLC and Mahanadi Coalfields Ltd. are sister PSUs and NLC’s requirements of coal could be met from Mahanadi Coalfields Ltd’s 70% share of production. This would fully meet the coal requirement of the two CPSUs to set up their power project and protect the interests of the central PSUs.”
Based on the arguments and the reasoning given by the coal ministry, the Prime Minister had approved the proposal on 1 October 2005.

The summons issued to former Prime Minister Manmohan Singh as an accused in the coal blocks allocation scam is probably a misdirection of the prosecution’s efforts. Not only will it probably go nowhere, but it will effectively shift the focus away from the real scamsters to the man who happened to figuratively head the coal ministry at that time – and who is highly unlikely to have derived any personal or pecuniary benefit from the misallocations.To be sure, the case does have some reason to drag Manmohan Singh’s name into it. For, he did have a direct role to play in changing the coal allocation pattern recommended by the Screening Committee set up for the purpose.The case, which involves the allocation of Talabira-II and Talabira-III coal blocks in Odisha’a Jharsuguda district in 2005, runs something like this: the blocks were originally allocated by the Screening Committee, headed by then Coal Secretary PC Parakh (also an accused in the case, along with Kumar Mangalam Birla of Hindalco), to the public sector Mahanadi Coalfields Ltd and Neyveli Lignite Corporation. But Birla wrote a letter to Manmohan Singh seeking his intervention. Singh directed him back to the coal ministry.

maxresdefault

Manmohan Singh in a file image. PTI image

The coal ministry, which too was headed by Manmohan Singh, initially said that Hindalco already had coal available from Mahanadi Coalfields which it had not used. Birla then wrote a second letter to the PMO explaining that the old coal linkage had not been used because a “bauxite mine lease relating to the aluminium plant had not materialised.” Birla also said that his request for Talabira-II had the backing of the Odisha Chief Minister, Naveen Patnaik.

It was after such to-ing-and-fro-ing that the PM gave his okay to changing the allocation pattern, and even this was not about favouring only Birla. The final allocation pattern was 70 percent to Mahanadi Coalfields, and 15 percent each to Neyveli and Hindalco in a joint venture that included both Talabira-I and Talabira-II. In this new arrangement, Neyveli did get short-changed, for it would get only around 29 percent of its requirements, and Hindalco over 80 percent. To remedy this, it was agreed that Neyveli could be given more coal from another block, Talabira-III.

Now, it is always possible to interpret Manmohan Singh’s intervention as an attempt to favour Birla, but the problem is that one can never know. The political authorities have to constantly take such decisions keeping the larger interests of the country in mind, including public sector and private interests.

The problem with summoning Manmohan Singh to appear in person at the CBI court in April is that it will be seen as needless political harassment. Singh has already given his version of events to the CBI when the agency queried him this January, and calling him to court to make the same statement is hardly going to give the case new legs.

The downside of dragging Manmohan Singh into the case physically is this: it will shift focus from the real crooks who may have made money in the coal block allocations to the politician under whose watch it happened. This is not likely to lead anywhere. The real case the CBI has to chase is who made the money – but that is not in sight.

In the Hindalco case, the Odisha CM clearly backed Birla vocally through a letter supporting the allocation, and all Manmohan Singh has to say in court is that in a federal set-up he has to respect the wishes of states as well.

The case against Manmohan Singh, or for that matter Naveen Patnaik, if he too is dragged in, will fail unless the CBI can prove mala fide intent in the final decision.

To prove this, they will have to show that either Singh or Patnaik (or even people close to them) had something personal to gain from changing the allocation to help Birla. The same has to be proved against Parakh and Kumar Birla, too – which is unlikely to happen.

What Manmohan Singh can be blamed for are three things.

First, he presided over an opaque process which enabled someone to make money from wayward coal block allocations.

Second, he failed to shift the process towards the transparency of auctions even though he once favoured it. Who, or what, forced him to change his mind will tell us who may have benefited from this. It is more than likely that Congress and state-level regional politicians will have been responsible for this, but there is no proof as of now.

Third, as PM, Manmohan Singh is ultimately responsible – politically – for what went wrong in his administration. His party may have paid a price for this in the recent elections.

However, unlike the 2G spectrum scam, where A Raja was clearly seen as the man behind the machinations to favour a few, in the coal block scam, one can spot only political failures, but no smoking gun leading to the real crooks.

This shows that the CBI is on the wrong trail. Manmohan Singh isn’t the one to chase; he may know who should be chased, but probably won’t tell. The questions to ask are (1) who, or what, made him change his mind on coal auctions, and (2) who may have got paid in each separate coal block allocation. On this, there is no progress whatsoever. The case in court won’t fly for lack of legal evidence.

FHM shoots top models & shows off!

The Argentinian model Romina Belluscio is the featured figure on the cover page of men’s magazine FHM Spain for the month of January 2011. The former Miss Argentina has posed wearing a set of leather lingerie that reveals her lush curves.

Filipina actress Ellen Adarna is the sexy cover star for the men’s magazine FHM Philippines for the month of December 2010. Ellen Adarna is proof of how the Internet can really make you famous. The December issue of FHM has everything you need to know about her – with her most stunning photo shoot.

Spanish actress Andrea Duro shows the chemistry of her beauty on the pages of men’s magazine FHM Spain for the month of December 2010. Beyond her role in physics or chemistry Yoli, Andrea Duro is news in these days for her role in a Christmas movie.

Shruti Hassan Top Indian Actress  Cover girl for FHM Magazine February 2014 edition sexy and hot pics.Here are few of the sizzling hottest pictures of the actress from the Magazine.
 Shruti hassan

 Shruti Hassan
 Shruti Hassan
 Shruti Hassan
 Shruti Hassan
 Shruti Hassan
 Shruti Hassan
 Shruti Hasan

Bruna Abdullah Photoshoot For FHM India Magazine October

Vaani Kapoor Hot and Sexy FHM Magazine Photoshoot Photos

Manasvi Mamgai Sizzling Hot FHM Magazine December 2014 Photos

Sunny Leone Hot and Sexy Photo Shoot Gallery For FHM Magazine in Green Saree

Sunny Leone sexy bikini photoshoot









Dr. Datsons Labs to partner with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015

Dr. Datsons Labs to partner with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015

 The Clinton Health Access Initiative (CHAI)’s Commitment to create a malaria-free zone in Africa awards contract to Dr. Datsons Labs to supply Artemisinin-based combination therapies” (ACTs) on a discounted price.

 

Monday,9th March 2015, Mumbai, Maharashtra. Indian Drug maker Dr. Datsons Labs Ltd specializing in manufacturing of Anti-Malarial drugs has received the proposal to supply the Artemisinin-based combination therapies” (ACTs) to The Clinton Health Access Initiative (CHAI), the healthcare project of the Clinton Foundation. Dr. Datsons Labs Ltd will be making a a significant deal though there Is a a minimum pricing that the company will be working on. The volume will be huge because it will be supplied to most of the African countries. In the UNITAID-CHAI Malaria Treatment Project 2015, other big players such as Cipla, Ipca & other Indian players are already on the approved list of The Clinton Health Access Initiative (CHAI) to supply the drugs.

Speaking on the deal with The Clinton Health Access Initiative (CHAI)’s UNITAID-CHAI Malaria Treatment Project 2015, Dr. Rajendra Kamat, Vice-Chairman & MD, Dr. Datsons Labs Ltd said, This is a huge order & the clauses in the Agreement are time bound with several quality aspects to adhere & Dr. Datsons Labs Ltd is fully equipped to meet the challenges of the order. We are also presently working on the recent orders of Marketing And Supply Agreement with Yemen’s AL-MUGDH PHARMA to sell its drugs in YEMEN, We are quite confident that we will bounce back again as a leading player both in international & domestic market. We will be working on two shifts from April onwards to the new orders received from Eubage Laboratory’s 20 innovative food supplements formulations coming under the neutraceutical foray.

 

Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. According to the World Health Organization, malaria caused an estimated 584,000 deaths worldwide in 2013. However, malaria is preventable and treatable. Increased investments and coordinated global health efforts have resulted in a 47 percent decrease in malaria mortality rates since 2000. With continued commitment and progress, a malaria-free generation will be within our reach.

Founded in 2002, by President William J. Clinton, the Clinton Health Access Initiative (CHAI) is a global health organization committed to strengthening integrated health systems around the world and expanding access to care and treatment for HIV/AIDS, Malaria and other illnesses. Based on the premise that business oriented strategy can facilitate solutions to global health challenges, CHAI acts as a catalyst to mobilize new resources and optimize the impact of these resources to save lives, via improved organization of commodity markets and more effective local management. CHAI helped the Government of South Africa to achieve a 53 percent price reduction for antiretroviral drugs; CHAI’s support will help the Government achieve US$960 million in savings over four years. In the past decade, remarkable advances have been made in treating and preventing malaria. Better medicines and long-lasting bed nets have been developed. Donor funding for malaria control has dramatically increased from $153 million in 2000 to over $1 billion in 2010. Indeed, the focus of many countries has recently shifted from malaria control to malaria elimination. Not surprisingly, this rapid infusion of new technology, increased funding, and policy reform has created a new set of challenges for the governments of malaria endemic countries. CHAI works in partnership with governments to address these challenges, creating evidence-based solutions tailor-made to each unique situation. In the past decade, remarkable advances have been made in treating and preventing malaria. Better medicines and long-lasting bed nets have been developed. Donor funding for malaria control has dramatically increased from $153 million in 2000 to over $1 billion in 2010. Indeed, the focus of many countries has recently shifted from malaria control to malaria elimination. Not surprisingly, this rapid infusion of new technology, increased funding, and policy reform has created a new set of challenges for the governments of malaria endemic countries. CHAI works in partnership with governments to address these challenges, creating evidence-based solutions tailor-made to each unique situation. CHAI’s work on malaria treatment began in Tanzania, which was, like most of Africa, flooded with cheap, ineffective malaria drugs called monotherapies. While government programs were making the switch to effective artemisinin-based combination therapies (ACTs), this treatment remained prohibitively expensive at the pharmacies where most Africans buy their drugs.

CHAI is currently working with AMFm countries to expand access to malaria treatment by increasing the market penetration of ACTs to over 50 percent in the next year. This initiative includes helping new ACTs gain market entry and uptake by providing technical assistance, regulatory expertise, and cost-optimization support to the companies that manufacture them. CHAI is also continuing our work to improve the sustainability and efficiency of malaria financing, including the exploration of novel mechanisms like cash-on-delivery, which pays for progress made toward targets. Additionally, CHAI is helping Swaziland advance toward becoming the first mainland African country to eliminate malaria by ramping up effective surveillance to track down and diagnose every case. Even a few years ago, people thought that eliminating malaria in a sub-Saharan African country was impossible and yet Swaziland is now on the verge of achieving that remarkable feat.

About Dr.Datsons Labs Ltd

Dr.Datsons Labs Ltd., formerly Aanjaneya Lifecare Limited, is an India-based integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing capabilities in Contract Research and Manufacturing Services, and active pharmaceutical ingredients. The Company focuses on anti-malarial and finished dosage forms (FDFs), catering to diverse therapeutic segments. The Company manufactures second generation anti-malarial APIs like quinine and salts as well as third generation anti-malarial products like Artemisinin-based salts. The Company engages in contract manufacturing for leading Indian pharmaceutical brands namely Wockhardt, Cipla, Zydus Cadila, Lupin and Glenmark, among others.  The Company’s subsidiaries include Eros Pharmachem Pte Limited, Aanj Pharmalabs Limited Fze, Fair Success (Hongkong) Limited and Dr. Datsons Labs Limited (the United Kingdom.

………………………………………………………………………………………………………

Contact

Mr. Yogesh Patel

Company Secretary

Dr. Datsons Labs.Ltd

Dr.Datsons House, Plot No W-91D Taloja MIDC 410208,

Raigad Dist, Maharashtra State, India

cs@drdatsons.com

Ph: (+91) 22-27402223 / 24

Fax: (+91) 22-27411837

Rising AAP must learn lessons if it intends to be an alternative force!

ar

 

Struck by internal differences, the AAP on Monday (March 2) appeared to be threatening to crack the whip against senior leaders like Yogendra Yadav and Prashant Bhushan at its national executive meeting on Wednesday, accusing them of attempting to “remove” Delhi Chief Minister Arvind Kejriwal from the post of party convener. At a press conference in New Delhi, senior AAP leader Sanjay Singh also targeted party patron Shanti Bhushan for his comment in an interview that Kejriwal should be replaced by Yadav.

“Someone from within the party, certain senior leaders are trying to remove Arvind Kejriwal from the post of National Convener, by targeting him and maligning the party,” Singh told reporters in New Delhi. Without naming Bhushan and Yadav, he referred to statements and letters by senior leaders which amounted to making the party a butt of ridicule and a “joke of us”.

Expressing displeasure over the leaking of letters to the media, the Political Affairs Committee (PAC) member, said the issues could be discussed in the party forum rather than bringing them before the public through the media. He announced that the party’s national executive would meet on Wednesday and decide on all issues including the latest controversy over differences in the party.

Singh parried questions when repeatedly asked whether the two senior leaders would be removed from the Political Affairs Committee (PAC). “I have only announced the date for the meeting. Have I announced the decisions that will be taken there,” he said in reply to questions on whether action will be taken against the leaders. Singh said that when at its national executive meeting held last week, Kejriwal had tendered his resignation, it was opposed by members who had insisted that he should continue as the AAP national convener.

“It was decided at the meet last week that Kejriwal will continue as the party chief and there is no question of removing him from the post. If this is the case, then how will the party work? “Will the volunteers like it. Those wanting to remove Kejriwal as party chief should also take the emotions of party workers into consideration,” Singh said. Crisis in the party intensified after Bhushan, in a letter to the national executive last week, said that the “one person -centric” campaign was making the party look like other parties and called for more “swaraj” within the organisation.

Along with Yadav, he also gave a joint letter to the national executive and demanded activation of an ethics and grievance committee. “One person-centric campaign, which was run during Delhi elections, is making our party look more and more like other conventional parties that are also one-person centric. The only difference being that we still claim that we are wedded to the principles of ‘swaraj’ while they don’t,” Bhushan had said in the letter.

The messy revelations coming out of the Aam Aadmi Party (AAP) on how Yogendra Yadav and Prashant Bhushan were removed from the party’s highest decision-making body, the Political Affairs Committee (PAC), offers grounds for hope, as yet. Yes, AAP certainly displays the typical characteristics of the Indian political party, subservient to one paramount leader.

Yes, AAP was founded to create an alternative to this kind of politics and it is unfortunate that the party has allowed victory in one state elections to go to its head. At the same time, it would still be premature to write off the experiment as a failure. There is still a chance to redeem the party and the new kind of politics it set out to champion, a fighting chance.

AAP
When people differ on strategic questions, they belong to different parties. When they differ only on tactical questions and on who should lead, they belong to different factions of the same party. There is nothing wrong with having factions. The democratic essence of a party is its ability to carry different factions along while it progresses along the strategic direction that all of them agree on and secures greater clarity on which faction is right about either tactic or leadership through debate, discussion and intra-party contestation. It is the Leninist ideal, not any democratic norm, that bars such contestation from involving the public and the party’s support base.

Yogendra Yadav and Prashant Bhushan certainly do not have the mass following that Arvind Kejriwal has. Yet, the 11-8 vote split in favour of removing the two leaders from the PAC shows that the intolerance of dissent does not have any overwhelming support within AAP. Yadav and Bhushan will do well to stay put within the party and fight it out to redeem AAP’s founding goals.

arvind kejriwal, kejriwal news, yogendra yadav, AAP, AAP news, prashant bhushan, AAP rift

Divisions in the Aam Aadmi Party deepened ahead of a crucial meeting of its national executive Wednesday, forcing party leader and Delhi Chief Minister Arvind Kejriwal to call it an “ugly battle” in which “I refuse to be drawn”.

But his lieutenants stepped up their attacks on leaders Yogendra Yadav and Prashant Bhushan saying they were out to extend a “vice-like grip” on all party wings. Bhushan, on his part, suggested that Kejriwal was open to “make certain compromises in politics”.

Talks were on late Tuesday night in the party to decide the fate of Yadav and Bhushan. An AAP source indicated that despite the harsh words against Bhushan, the leadership is still open to “some form of a reconciliation with him but not Yadav”.

Kejriwal signalled he could skip the national executive meeting — unwell, he plans to leave for Bangalore on Thursday for naturopathic treatment — while Bhushan, though under fire, may attend.

The BattleThe odds are heavily stacked against Bhushan and Yadav since the Wednesday meeting will be limited to 27 voting members of the national executive where Kejriwal’s supporters are in a majority. AAP spokesperson Deepak Bajpai said: “There are 21 members of the national executive and six state representatives.”

The executive has the powers to elect and change the political affairs committee which has Bhushan and Yadav as its members.Last week, Kejriwal had offered to step down as national convenor of the party but the executive rejected it.As the differences within came out in the open, Kejriwal broke his silence Tuesday to tweet: “I am deeply hurt and pained by what is going on in the party. This is betrayal of trust that Delhi posed in us. I refuse to be drawn in this ugly battle. Will concentrate only on Delhi’s governance. Will not allow public trust to be broken under any circumstances.”

AAP senior Shanti Bhushan, father of Prashant Bhushan, made conciliatory noises: “Differences in the party are not right. Prashant Bhushan and Yogendra Yadav should support Kejriwal.”

But his son told NDTV that he had not spoken to Kejriwal in several days and “I feel we have to be absolutely firm on our ethical principles but Arvind differs at times and says we need to make certain compromises in politics.”

AAP leaders hit back at the Bhushans. Ashish Khetan tweeted: “Those who are floating the ridiculous one man party theory wanted to make AAP one family party. Father son daughter trio of Shanti Prashant & Shalini wanted to have a vice-like grip on all party wings, from PAC to policy committee to NE.”

AAP, Yogendra Yadav, Yogendra Yadav AAP, Aam Aadmi Party, Arvind KejriwalSince the Lok Sabha rout, Yadav and senior lawyer Prashant Bhushan have raised questions on inner-party democracy and a personality cult within the AAP revolving around Kejriwal.Ashutosh, head of the Delhi unit, also took to Twitter: “Prashant ji should have raised issue of personality cult in NE, to be held tomorrow instead in media. NE should have discussed/taken a call.
NE is highest decision making body/is empowered to decide on any issue/can direct anyone accordingly. Best  forum to discuss/decide.”

“Shanti Bhushan ji sud explain why did he say Arvind to be replaced with Yogendra during elections and after NE meet. That is indiscipline. Shanti Bhushan ji should also explain what was the conspiracy to replace Arvind with Yogendra ? Did it not tarnish the image of party,” Ashutosh tweeted.

Union Budget 2015 may open wider global investments in 2015-16

 

 

Indian and international investors are optimistic about the prospects for accelerating growth in India, after New Delhi revealed a budget that will slow the pace of fiscal consolidation, while stepping up public spending in infrastructure.In his first full budget since Narendra Modi’s government came to power in May, Arun Jaitley, finance minister, said New Delhi would ease off a previously outlined fiscal road map, which was aiming to reduce the fiscal deficit to 3 per cent of gross domestic product by 2016-17.Instead, New Delhi delayed the target a year, using the leeway to invest billions of dollars into infrastructure. The fiscal deficit target for the next financial year, which starts in April, will be 3.9 per cent of GDP, higher than the anticipated 3.6 per cent. The fiscal deficit is currently 4.1 per cent of India GDP.Arvind Subramanian, chief economic adviser, has argued India’s corporate sector is heavily indebted to finance large-scale investments, and the government must kick-start investment.New Delhi’s capital expenditure is budgeted for a 25 per cent increase next year, including a one-third jump in railway investment, a 127 per cent surge in spending on highways, and five new 4,000 megawatt power projects.“The budget is a fine balancing act between fiscal consolidation and creating enabling conditions for growth and job creation,” wrote Rohini Malkani, Citigroup’s chief India economist.Pranjul Bhandari, HSBC’s chief India economist, called the budget “positive” for growth and the rupee, but warned that “having taken a breather from the ambitious fiscal consolidation step”, New Delhi will be closely monitored on its spending.Some warned that New Delhi may struggle to fulfil its ambitious investment targets, stymied by the same problems of land and environmental clearances that hinder private sector projects. Mr Modi wants to make it easier to acquire land for industry and infrastructure, but his proposed changes are facing resistance.“The key thing is going to be the implementation of the infrastructure budget, which of course is tied in closely with the land law, which is again up in the air,” said Atul Punj, chairman of Punj Lloyd Group, the conglomerate. “The money is not the issue. The ability to utilise the money will be the issue.”

Mr Jaitley said the government was planning to prepare large infrastructure projects, with ready clearances, and auction them to private companies to execute — what it called a “plug-and-play” model.

On the tax front, Mr Jaitley reaffirmed his determination to implement a nationwide general sales tax system by April 1 2016, replacing the jumble of local fees and taxes that prevent India from being a single market for goods and services. The GST has long been seen as a “game-changer” for business.

Mr Jaitley also revealed what one analyst called a politically brave plan to cut the nominal corporate income tax rate from 30 to 25 per cent over the next four years, while simultaneously reducing exemptions.This year, New Delhi is scrapping a low-yielding 1 per cent “wealth tax” on fixed assets over Rs3m ($48,700), while raising an existing 10 per cent income tax surcharge on India’s “super-rich” — those earning above Rs10m ($160,000) a year — by an additional 2 percentage points, to 12 per cent.Consumers will also be also affected, as service tax is being increased from 12 to 14 per cent, making much of the discretionary spending of the nascent middle class — on such items as dining out, entertainment, and travel — more expensive.

Mr Jaitley promised a host of structural reforms, including greater use of direct benefit transfers to replace subsidies and the creation of a true bankruptcy law. He also pledged a crackdown on “black money” held abroad, threatening jail terms of up to 10 years in prison.India’s stock market, which fluctuated through a special trading period while the budget was revealed, closed up 0.5 per cent. But while the corporate sector gave the budget a thumbs-up, plaudits were not universal, with some warning that it depended on “optimistic” assumptions about both growth and revenues.Manmohan Singh, the former prime minister, called Mr Jaitley a “lucky” finance minister, who had inherited favourable macroeconomic indicators, due to falling global oil prices. But Mr Singh said the government should use the benign external environment to push fiscal consolidation.“Tomorrow, if anything happens with the oil prices, we will have less cushion to deal with this,” Mr Singh told NDTV news. “I therefore worry there is not enough emphasis on fiscal consolidation and macroeconomic stabilisation.”

Eswar Prasad, an economist with Cornell University and the Brookings Institution, also suggested the budget was a missed opportunity to utilise favourable circumstances as “a launching pad for substantive fiscal and other reforms,” especially major subsidy reform.“This budget takes a few small steps rather than a giant leap, and fails to take full advantage of a propitious alignment of stars for the Indian economy,” Mr Prasad said.

[wordpress_social_login]

Biocon Chief Kiran Mazumdar Shaw on Union Budget 2015

The Finance minister’s budget speech was very compelling. He gave me an impression that he has broadly met everyone’s expectations. The fine print of the budget needs to be carefully analysed to understand the impact that this budget would have. Now, it is about delivering what is required to achieve the key points of the 2015 budget proposal, which doubles up as a very good vision document on the direction of the Indian Economy. I think the Finance Minister has touched upon a lot of key areas, but now it is about delivering on the positive proposals put forth in this budget.

In terms of addressing key constituencies, the Finance Minister did a good job of addressing both the social sector and the corporate sector. This budget has certainly raised important questions in the realm of resource management. How do you raise resources and how do you free up resources? The measures taken to monetize gold is a key step forward. Moreover, the budget has made a strong attempt to put money back in the hands of the people. Raising Health Insurance Premiums exemption limit, increasing National Pension Scheme contribution exemption limit along with increasing Transport Allowance exemption effectively means that an individual tax payer can save up to Rs. 4,44,200.

The easing of corporate tax is definitely going to bring cheer to corporates, as it will relieve them of a high tax burden and they can direct their resources to making Investments that help India grow. In terms of other taxation reforms, the government has made a positive move by ensuring that the Wealth Taxes are abolished and 2% surcharge is added to tax individuals whose taxable income is above 1 crore. Apparently, this measure will bring in an additional Rs. 9,000 crores into the government coffers and hence, it is a positive proposal.

Addressing the “Make In India” Mantra

The Finance Minister rightly touched upon the fact that the Skill India and Digital India initiatives are drivers for “Make In India”. The thrust laid on indigenous defence production as well as the focus on renewable energy will certainly push the agenda for “Make In India” forward.

Infrastructure Push

There has been a corpus of Rs. 70,000 crores allocated to Infrastructure, which will definitely lead to the development of major infrastructure projects. Along with the proposal to set up major power plants, the infrastructure push in this budget is set to surge India ahead. The proposal to revitalise the PPP model for infrastructure development and the subsequent bearing of majority risk by the govt. will definitely yield positive results for infrastructure. Additionally, the tax – free bonds in rail roads and irrigation projects will spur investments in critical infrastructure.

Laying the Groundwork to Enable ‘A Startup Culture’

I was impressed by the Finance Minister’s announcement of the Atal Innovation Mission to be established which will draw on expertise of entrepreneurs, and researchers to foster scientific innovations. An allocation of Rs. 150 crores has been made for this purpose. Moreover, it is heartening to see the Finance Minister to allocate Rs. 1000 crores for start-ups. Although, the fine print will give more clarity on this allocation, but nevertheless it is a boost. The talk of creating world class incubators is welcome, as long as they facilitate the creation of incubators by people who know the business.

Access to Health

Healthcare is probably one of the sectors, which hasn’t been given the due importance in this budget. The Finance Minister could have proved its commitment to the universal health coverage and increased public health spending. This was one of the areas, where the budget could have done much more and clearly it failed in this regard.

Having said that, the setting up of AIIMS in Jammu and Kashmir, Punjab, Tamil Nadu, Himachal Pradesh, Bihar and Assam pushes forth Healthcare education and research in these states.

Conclusion

The Finance Minister has certainly laid a very positive roadmap for the future. One can only hope that the govt. delivers on its budget proposals in an effective manner and reaches the destination that it has shown. Clearly, India is Poised and the Flight Path is cleared for takeoff!

Kiran Mazumdar Shaw*

AAP ideas are now part of Union Finance Minister’s Budget 2015 – Meera Sanyal

The Finance Minister has presented his first full-fledged Union Budget under the most favourable political and economic circumstances. Though some welcome measures were announced, the budget sadly missed the opportunity to present a clear vision on the much-awaited road map to ‘Achhe Din’.

Clarity on top governmental priorities — how and where 10 lakh jobs per month would be created and how India would move up the rankings from its lowly position of 142 on the Ease of Doing Business — were conspicuous by their absence. It did not add comfort that the plan is to set up yet another committee to suggest such steps. Industry leaders have complained that the “pro-business prose hasn’t translated into on-ground policy reality”.

Incorporating AAP ideas

We are extremely happy that several of the Aam Aadmi Party’s ideas have been adopted — Mr. Prashant Bhushan’s suggestion on a comprehensive law to combat Black Money and the Pradhan Mantri Vidya Lakshmi Scheme, which mirrors AAP’s Higher Education Guarantee Scheme, are examples.

We appreciate the introduction of Insurance-based social security schemes, which provide a much-needed safety net to those at the bottom of the pyramid. Similarly the monetisation of gold will hopefully bring this precious metal out from “under the pillow” into being a productive part of our economy. The Bankruptcy law, deepening of the bond markets, capital market reforms, and bringing NBFCs under the SARFAESI Act are all positive.

However, there is serious concern with the approach to taxation. Many feel that the corporate sector is being appeased with tax cuts and exemptions — though the fine print shows an increase of 0.25 per cent! With increased service tax and excise duty, the fundamentally regressive nature of Indian taxation (decrease in direct taxation and increase in indirect taxation) has worsened and the burden on the Aam Aurat and the Aam Aadmi has increased.

In a huge surprise, the Finance Minister seemed to walk away completely from the proposed Direct Tax Code reforms. There were minor exemptions for the middle class but no rationalisation or simplification of taxes, with no concrete measures being taken to widen the tax base or improve our very low tax-to-GDP ratio.

Of equal concern is the lack of a committed timetable or implementation plan for the General Sales Tax (GST). With a majority in the Centre and in several States, it is hard to understand why the BJP government is not pushing ahead swiftly on this much-needed reform.

Another area of concern is the shifting of the fiscal consolidation goalposts. Given the positive head winds of declining fuel costs, sticking with a fiscal deficit target of 3.6 per cent was achievable. Mr. Jaitley’s 8 per cent GDP growth numbers use a different base year for price changes and a new way of calculating GDP at market price rather than factor cost. This is something that both RBI Governor Raghuram Rajan and Chief Economic Advisor Arvind Subramanian have been puzzled by.

The idea of increasing allocations of untied funds to States is welcome and aligns with the concepts of Swaraj and decentralisation. However institutional mechanisms to report on actual allocations and outcomes are required. Though an allocation of 42 per cent to States gives the perception of greater funds being given to States, one must note that this has been accompanied by huge spending cuts in social sector spending, and leaves no directives on essential service delivery to States. For example, expenditure on Sarva Shiksha Abhiyaan has gone down from Rs.28,000 crore to Rs.22,000 crore, the Integrated Child Development Scheme from Rs.16,000 crore to Rs.8,000 crore, and the Mid-Day Meal Scheme from Rs.13,000 crore to Rs.9,000 crore.

Education received token mentions in the form of a few new IITs, IIMs and AIIMS instead of fundamental overhauls while health and environment did not appear to be on the agenda. There was also no mention of allocations for the ‘One Rank One Pension’ promise made to the Armed Forces. Though there was a Rs.1,000 crore allocation to the Nirbhaya fund, in the interest of transparency it would have been good for the Finance Minister to share information about the fund’s non-utilisation in consecutive years. The Prime Minister’s Office itself stopped the directive to create one-stop crisis centres for women. If utilisation of funds is not a focus, budgeting will regrettably, especially for areas as critical as women’s security, remain a token farce.

This was a unique opportunity to present a bold and visionary budget to set India on the path of sustained and inclusive growth — but regrettably the 2015 Union Budget, will go down as an opportunity missed.

(Meera Sanyal is on the Aam Aadmi Party’s National Committee for Policy. Roshan Shankar works full-time at the AAP.)

India’s Dr. Datsons Labs Ink Marketing And Supply Agreement with Yemen’s AL-MUGDH PHARMA to sell its drugs in YEMEN.

Yemen Deal

India’s Dr. Datsons Labs Ink Marketing And Supply Agreement with Yemen’s AL-MUGDH PHARMA to sell its drugs in YEMEN.

Dr. Datsons Labs to export Anti-Malarial Drugs worth 80 Crore to Yemen, deal to boost Dr. Datson’s export business.

Dr. Datsons Labs Ltd, India and AL-MUGDH PHARMA of Yemen have signed a licensing, distribution and supply deal, under which the distribution company will market Anti-Malarial Drugs. Dr. Datsons Labs Ltd, HSL Code: AANLIF, BSE Code: 533412, NSE Symbol: DRDATSONS,ISIN INE928K01013 should trade higher after entering into a binding Memorandum of Understanding with Almugdh Pharma, Yemen to distribute its anti-malarial product. Shares of Dr.Datsons Labs Limited was last trading in BSE at Rs.6.70 as compared to the previous close of Rs. 6.97. Once the darling of the stock market, Dr. Datsons Labs has been on a series of downfalls following the market conditions. Experts believe that with the new Management at the helm effected by the Board this month, some aggressive actions may be noticed including the deals underway with overseas companies for capital inflow.  The Company is also looking to widen its product basket to cater to the regulated & semi regulated market.

According to Mr. Sameer Talim, CEO, Dr. Datsons Labs Ltd, “the talk between the two companies was going on for the last six months & there are certain regulatory aspects that need to be addressed before the commercialization of the 5 products to be exported to AL-MUGDH PHARMA. These products include Codeine Phosphate U.S.P. – 30 mg , ARTESUNATE 100 MG + AMODIAQUINE 270 MG, MEFLOQUINE HCL 250MG+ARTESUNATE 200MG, ARTESUNATE 50 MG + AMODIAQUINE 153 MG,QUININE SULPHATE 300 MG. “. Dr. Datsons Labs is revamping its factory in Pune to cater to the overseas market. The estimated order for the Yemen is to the tune of 80 crore. We also have a commitment to manufacture Nutraceuticals for Belgium company Eubage which is awaiting for the final clearances.

It may be note that The pharmaceutical market in Gulf Cooperation Council (GCC) countries and specially Yemen is growing rapidly and is projected to grow into an estimated US$10-billion industry by 2020. There were 46 pharmaceutical manufacturing plants in the GCC and Yemen in 2010. The combined investments of the region in this sector during the same year stood at US$830-million, providing jobs for 8,000 people, yet the region still imports the bulk of its medicines. This industry was growing six percent annually but local pharmaceutical companies have not been able to meet this growth. The GCC and Yemen was currently importing 90% of its medicines. “There are significant opportunities for growth and expansion of this sector in the GCC so that in future it will be able to meet a substantial part of the requirements of the region with the possibility of exporting them to neighboring countries,”

AL-MUGDH PHARMA is Yemen’s leading healthcare firm engaged in import, distribution and marketing agents of pharmaceuticals , medical disposables and medical appliances. Ministry Of Health, Chamber Of Commerce and Ministry of Industry and Trade has recognized AL-MUGDH PHARMA  as one of the leading Pharmaceutical importer , wholesaler and distributors for branded & amp; generic products of major multinationals , & amp; Multinational companies and surgical products , Eye drops & it has a good base of clients, a net of distributors equipped with all facilities and well educated and trained ones.

Dr.Datsons Labs Ltd., formerly Aanjaneya Lifecare Limited, is an India-based integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing capabilities in Contract Research and Manufacturing Services, and active pharmaceutical ingredients. The Company focuses on anti-malarial and finished dosage forms (FDFs), catering to diverse therapeutic segments. The Company manufactures second generation anti-malarial APIs like quinine and salts as well as third generation anti-malarial products like Artemisinin-based salts. The Company engages in contract manufacturing for leading Indian pharmaceutical brands namely Wockhardt, Cipla, Zydus Cadila, Lupin and Glenmark, among others.  The Company’s subsidiaries include Eros Pharmachem Pte Limited, Aanj Pharmalabs Limited Fze, Fair Success (Hongkong) Limited and Dr. Datsons Labs Limited (the United Kingdom.